Muhammad A. Rizvi
Muhammad A. Rizvi publishes mostly in Oncology, Cardiology and Cardiovascular Medicine and Surgery, on topics such as Cancer Immunotherapy and Biomarkers, Chemotherapy-induced cardiotoxicity and mitigation and Urinary and Genital Oncology Studies.
- World rank
- #840,417 of 7,710,434 ranked researchers
- Rank in United States
- #279,129 of 1,627,098
- Works
- 22
- Citations
- 1.7k
- Citations per work
- 77.0
What does Muhammad A. Rizvi research?
Muhammad A. Rizvi's work is mostly in Medicine (76%), Immunology and Microbiology (8%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1775.9%
- Medicine1775.9%
- Everything else416.5%
- Life Sciences27.6%
- 1Oncology26% of their works
- 2Cardiology and Cardiovascular Medicine18% of their works
- 3Surgery17% of their works
- 4Radiology, Nuclear Medicine and Imaging9% of their works
- 5Immunology8% of their works
- 6Epidemiology6% of their works
Research topics
- Cancer Immunotherapy and Biomarkers
- Chemotherapy-induced cardiotoxicity and mitigation
- Urinary and Genital Oncology Studies
- Atherosclerosis and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Bladder and Urothelial Cancer Treatments
- Angiogenesis and VEGF in Cancer
- Viral Infections and Immunology Research
Which keywords describe Muhammad A. Rizvi's research?
The keywords of their largest research topics: Immune Checkpoint Blockade, PD-1 and PD-L1, Chemotherapy, Anthracyclines, Doxorubicin, Primary Urethral Carcinoma, Urachal Carcinoma and Atherosclerosis.
- Viral Infection
- Myocarditis
- Immune Response
- Cardiac Imaging
- Atherosclerosis
- Primary Urethral Carcinoma
- Anthracyclines
- PD-1 and PD-L1
- Immune Checkpoint Blockade
- Chemotherapy
- Doxorubicin
- Urachal Carcinoma
- Bladder Cancer
- Coronary Artery Disease
- Urothelial Carcinoma
- VEGF
- endothelial progenitor cells
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 17 words, with their numbers
- Immune Checkpoint Blockade121 topic
- PD-1 and PD-L1121 topic
- Chemotherapy92 topics
- Anthracyclines61 topic
- Doxorubicin61 topic
- Primary Urethral Carcinoma41 topic
- Urachal Carcinoma41 topic
- Atherosclerosis31 topic
- Bladder Cancer31 topic
- Cardiac Imaging31 topic
- Coronary Artery Disease31 topic
- Immune Response31 topic
- Urothelial Carcinoma31 topic
- Myocarditis21 topic
- VEGF21 topic
- Viral Infection21 topic
- endothelial progenitor cells21 topic
Where does Muhammad A. Rizvi work?
Muhammad A. Rizvi's main affiliation in the publication record is Lehigh Valley Hospital-Pocono, United States.
How many publications and citations does Muhammad A. Rizvi have?
OpenAlex counts 22 works and 1,695 citations for Muhammad A. Rizvi, an h-index of 13, ranking #840,417 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Muhammad A. Rizvi. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.